iBio, Inc. (NYSE:IBIO – Free Report) – Equities researchers at Brookline Capital Management upped their Q1 2025 earnings per share (EPS) estimates for shares of iBio in a research report issued to clients and investors on Monday, September 23rd. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of ($0.46) per share for the quarter, up from their previous forecast of ($0.53). Brookline Capital Management has a “Buy” rating and a $3.60 price objective on the stock. The consensus estimate for iBio’s current full-year earnings is ($6.32) per share. Brookline Capital Management also issued estimates for iBio’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.74) EPS.
Separately, Chardan Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of iBio in a report on Monday, June 3rd.
iBio Stock Performance
Shares of IBIO opened at $1.95 on Thursday. The company’s 50 day moving average price is $1.94. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.08 and a quick ratio of 1.69. iBio has a one year low of $1.02 and a one year high of $7.83.
Institutional Trading of iBio
Large investors have recently bought and sold shares of the business. Lynx1 Capital Management LP acquired a new position in iBio in the first quarter valued at approximately $2,436,000. Opaleye Management Inc. bought a new position in iBio during the first quarter worth $2,761,000. Finally, Ikarian Capital LLC acquired a new stake in iBio in the first quarter worth $2,436,000. 7.90% of the stock is currently owned by institutional investors and hedge funds.
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Featured Articles
- Five stocks we like better than iBio
- Overbought Stocks Explained: Should You Trade Them?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- How to Effectively Use the MarketBeat Ratings Screener
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
